Scopolamine (hydrobromide trihydrate)

Scopolamine (Hyoscine) hydrobromide trihydrate is a high-affinity muscarinic antagonist that can cross the blood-brain barrier. Scopolamine hydrobromide trihydrate competitively antagonizes 5-HT₃ receptors with an IC₅₀ of 2.09 μM. Scopolamine hydrobromide trihydrate can induce cognitive and memory deficits in animals. Scopolamine hydrobromide trihydrate can be used in the research of preventing postoperative nausea and vomiting, motion sickness, nervous system diseases, etc^{[1][2][3][4][5]}. In Vitro:receptors (IC₅₀ = 928 μM) and increases the expression of α7 nACh receptors. Scopolamine hydrobromide trihydrate displays concentration-dependent competition with 0.6 nM [³H]Granisetron, yielding an average pK_ii = 6.76 μM). Concentration-dependent competition of fluorescently labeled form of Granisetron (HY-B0071) with Scopolamine hydrobromide trihydrate gives an average pK_i of 5.31 (K_i = 4.90 μM). Scopolamine hydrobromide trihydrate blocks muscarinic receptors and induces a cognitive deficit^[1].
Scopolamine (0.1-3 mM; for 24 hours) hydrobromide trihydrate induces cytotoxicity, ROS generation and apoptosis of SH-SY5Y cells^[6].
In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Scopolamine (1 mg/kg; i.p.; once) induces memory impairment associated with attenuation of cholinergic neurotransmission, as well as an increases of processes connected with oxidative stress in the brain in mice^[7].
Scopolamine can be used to induce memory impairment models^[4].